Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial
Meg Jardine(Royal North Shore Hospital), Vivekanand Jha(The George Institute for Global Health), Carol A. Pollock(The University of Sydney), Vinay Rathore(All India Institute of Medical Sciences Raipur), Ashpak Bangi(Axis Multispecialty Hospital), Abhinav Bassi(George Institute for Global Health), Carinna Hockham(Université de Montpellier), Michelle M. Cummins(The University of Sydney), Andrew J. McLachlan(The University of Sydney), Christine Jenkins(The University of Sydney), Arlen Wilcox(The University of Sydney), Angus Ritchie(Concord Repatriation General Hospital), Mark Jones(Belfast Health and Social Care Trust), Louise M. Burrell(Austin Health), Sanjay D’Cruz(Government Medical College and Hospital), Sradha Kotwal(The George Institute for Global Health), Lalit Gupta(Maulana Azad Medical College), Simon Finfer(The George Institute for Global Health), James M. McGree(Queensland University of Technology), Tom Snelling(National Centre for Immunisation Research & Surveillance)
Cited by 40
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Worldwide access to treatment for end-stage kidney disease: a systematic review
|The Lancet|2015|2.3k
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
|Journal of Clinical Epidemiology|2012|1.2k